PUBLICATIONS | Professor Shudong Wang & Team
Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
Saiful Islam; Muhammed H. Rahaman; Mingfeng Yu; Benjamin Noll; Jennifer H. Martin; Shudong Wang; Richard Head
Kinase inhibitors: Opportunities for Small Molecule Anticancer Immunotherapies
Ava Safaroghli-Azar; Fatemeh Emadi; Jimma Lenjisa; Laychiluh Mekonnen; Shudong Wang
Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation
Biruk Sintayehu Fanta; Jimma Lenjisa; Theodosia Teo; Lianmeng Kou; Laychiluh Mekonnen; Yuchao Yang; Sunita K. C. Basnet; Ramin Hassankhani; Matthew J. Sykes; Mingfeng Yu; Shudong Wang
An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
Abel T. Anshabo; Laychiluh Bantie; Sarah Diab; Jimma Lenjisa; Alemwork Kebede; Yi Long; Gary Heinemann; Jasmine Karanjia; Benjamin Noll; Sunita K. C. Basnet; Manjun Li; Robert Milne; Hugo Albrecht; Shudong Wang
Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation
Renjie Chen; Ramin Hassankhani; Yi Long; Sunita K. C. Basnet; Theodosia Teo; Yuchao Yang; Laychiluh Mekonnen; Mingfeng Yu; Shudong Wang
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
Saiful Islam; Theodosia Teo; Malika Kumarasiri; Martin Slater; Jennifer H. Martin; Shudong Wang; Richard Head
DOI: 10.3390/ph15101186
An Overview of CDK3 in Cancer: Clinical Significance and Pharmacological Implications
Theodosia Teo; Sara Kasirzadeh; Hugo Albrecht; Matthew J. Sykes; Yuchao Yang; Shudong Wang
Repurposing Existing Therapeutics, Its Importance In Oncology Drug Development: Kinases as a Potential Target
Saiful Islam; Shudong Wang; Nikola Bowden; Jennifer Martin; Richard Head
DOI: 10.1111/bcp.14964
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer
DOI: 10.1021/acs.jmedchem.1c02139
US FDA Approved Small-Molecule Kinase Inhibitors for Cancer Therapy
Mingfeng Yu; Solomon Tadesse; Shudong Wang
In Burger’s Medicinal Chemistry and Drug Discovery, D.J. Abraham (Ed.)., 2022 DOI: 10.1002/0471266949.bmc214.pub2
A Combination Of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
Abdullah Al Emran; Hsin-Yi Tseng; Dilini Gunatilake; Stuart J. Cook; Farzana Ahmed; Shudong Wang; Peter Hersey; Stuart J. Gallagher; Jessamy C. Tiffen
Journal of Investigative Dermatology, 2021
DOI: 10.1016/j.jid.2020.12.038
Discovery of a Potent, Highly Selective, and Orally Bioavailable Inhibitor of CDK8 Through a Structure-Based Optimisation
Mingfeng Yu; Yi Long; Yuchao Yang; Manjun Li; Theodosia Teo; Benjamin Noll; Stephen Philip; Shudong Wang
European Journal of Medicinal Chemistry, 2021
DOI: 10.1016/j.ejmech.2021.113391
Discovery of Novel 4-Azaaryl-N-Phenylpyrimidin-2-Amine Derivatives as Potent and Selective FLT3 Inhibitors for Acute Myeloid Leukaemia with FLT3 Mutations
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
Abel T. Anshabo; Robert Milne; Shudong Wang; Hugo Albrecht
Frontiers in Oncology, 2021
DOI: 10.3389/fonc.2021.678559
A First-In-Class CDK4 Inhibitor Demonstrates In Vitro, Ex-Vivo and In Vivo Efficacy Against Ovarian Cancer
Laychiluh Bantie; Solomon Tadesse; Jimma Likisa; Mingfeng Yu; Benjamin Noll; Gary Heinemann; Noor A. Lokman; Carmela Ricciardelli; Martin K. Oehler; Andrew Beck; Rupal Pradhan; Robert Milne; Hugo Albrecht; Shudong Wang
Gynecologic Oncology, 2021
DOI: 10.1016/j.ygyno.2020.09.012
Potent and Orally Bioavailable CDK8 Inhibitors: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation
DOI: 10.1016/j.ejmech.2021.113248
Structure-Based Design of Highly Selective 2,4,5-Trisubstituted Pyrimidine CDK9 Inhibitors as Anti-Cancer Agents
DOI: 10.1016/j.ejmech.2021.113244
Mnk Inhibitors: A Patent Review
DOI: 10.4155/ppa-2020-002
CDK12: A Potential Therapeutic Target in Cancer
DOI: 10.1016/j.drudis.2020.09.035
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Targeting CDK2 in Cancer: Challenges and Opportunities For Therapy
Solomon Tadesse; Abel T. Anshabo; Neil Portman; Elgene Lim; Wayne Tilley; Elizabeth C. Caldon; Shudong Wang
Drug Discovery Today, 2020
DOI: 10.1016/j.drudis.2019.12.001
CDKI-73 is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion
Alexandra Sorvina; Tetyana Shandala; Shudong Wang; David J. Sharkey; Emma Parkinson-Lawrence; Stavros Selemidis; Douglas A Brooks
Cells, 2020
DOI: 10.3390/cells9020372
EZH2 Inhibitors Abrogate Upregulation of Trimethylation of H3K27 by CDK9 Inhibitors and Potentiate its Activity against Diffuse Large B-Cell Lymphoma
Shao Xie; Fan Wei; Yiming Sun; Yinglei Gao; Lulu Pan; Minjia Tan; Shudong Wang; Jian Ding; Yi Chen
Haematologica, 2020
DOI: 10.3324/haematol.2019.222935
Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma
Günther H. S. Richter; Tim Hensel; Oxana Schmidt; Vadim Saratov; Kristina von Heyking; Fiona Becker-Dettling; Carolin Prexler; Hsi-Yu Yen; Katja Steiger; Simone Fulda; Uta Dirksen; Wilko Weichert; Shudong Wang; Stefan Burdach; Beat W. Schäfer
Cancers (Basel), 2020
DOI: 10.3390/cancers12020304
Efficacy of Combined CDK9/BET Inhibition in Preclinical Models of MLL-Rearranged Acute Leukemia
Hannah McCalmont; Ka Leung Li; Luke Jones; John Toubia; Sarah C. Bray; Debora A. Casolari; Chelsea Mayoh; Saumya E. Samaraweera; Ian D. Lewis; Rab K. Prinjha; Nicholas Smithers; Shudong Wang; Richard B. Lock; Richard J. D’Andrea
Blood Advances, 2020
DOI: 10.1182/bloodadvances.2019000586
Targeting CDK9 for Treatment of Colorectal Cancer
Muhammed H. Rahaman; Frankie Lam; Longjin Zhong; Theodosia Teo; Julian Adams; Mingfeng Yu; Robert Milne; Chris Pepper; Noor A. Lokman; Carmela Ricciardelli; Martin K. Oehler; Shudong Wang
Molecular Oncology, 2019
DOI: 10.1002/1878-0261.12559
CDKI-73: An Orally Bioavailable and Highly Efficacious CDK9 Inhibitor Against Acute Myeloid Leukemia
Muhammed H. Rahaman; Yingyi Yu; Longjin Zhong; Julian Adams; Frankie Lam; Peng Li; Ben Noll; Robert Milne; Jun Peng; Shudong Wang
Invest New Drugs, 2019
DOI: 10.1007/s10637-018-0661-2
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Solomon Tadesse; Elizabeth C. Caldon; Wayne Tilley; Shudong Wang
Journal of Medicinal Chemistry, 2019
DOI: 10.1021/acs.jmedchem.8b01469
Synthesis and Evaluation of 2'H-Spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione Derivatives as Mnk Inhibitors
Ahmed M. Abdelaziz; Sunita K. C. Basnet; Saiful Islam; Manjun Li; Solomon Tadesse; Hugo Albrecht; Cobus Gerber; Mingfeng Yu; Shudong Wang
Bioorganic & Medicinal Chemistry Letters, 2019
DOI: 10.1016/j.bmcl.2019.07.043
Discovery of CDK5 Inhibitors through Structure-Guided Approach
Nishat Z. Khair; Jimma L. Lenjisa; Solomon Tadesse; Malika Kumarasiri; Sunita K. C. Basnet; Laychiluh B. Mekonnen; Manjun Li; Sarah Diab; Matthew J. Sykes; Hugo Albrecht; Robert Milne; Shudong Wang
ACS Medicinal Chemistry Letters, 2019
DOI: 10.1021/acsmedchemlett.9b00029
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of In Vitro Anti-Leukaemic Activity
Ahmed M. Abdelaziz; Sarah Diab; Saiful Islam; Sunita K. C. Basnet; Benjamin Noll; Peng Li; Laychiluh B. Mekonnen; Jingfeng Lu; Hugo Albrecht; Robert W. Milne; Cobus Gerber; Mingfeng Yu; Shudong Wang
Medicinal Chemistry, 2019
DOI: 10.2174/1573406415666181219111511
Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer
Neil Portman; Sarah Alexandrou; Emma Carson; Shudong Wang; Elgene Lim; Elizabeth C. Caldon
Endocrine-Related Cancer, 2019
DOI: 10.1530/ERC-18-0317
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Discovery and Pharmacological Characterization of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents
British Journal of Pharmacology, 2018
DOI:10.1111/bph.13974
In Search of Novel CDK8 Inhibitors by Virtual Screening
Malika Kumarasiri; Theodosia Teo; Mingfeng Yu; Stephen Philip; Sunita K. C. Basnet; Hugo Albrecht; Matthew J. Sykes; Peng Wang; Shudong Wang
Journal of Chemical Information and Modeling, 2017
DOI: 10.1021/acs.jcim.6b00711
Inhibition of CDK9 Induces Apoptosis and Potentiates the Effect of Cisplatin in Hypopharyngeal Carcinoma Cells
Shengda Cao; Yingyi Yu; Shangren Chen; Dapeng Lei; Shudong Wang; Xinliang Pan; Jun Peng
Biochemical and Biophysical Research Communications, 2017
DOI: 10.1016/j.bbrc.2016.11.049
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
Solomon Tadesse; Mingfeng Yu; Laychiluh B. Mekonnen; Frankie Lam; Saiful Islam; Khamis Tomusange; Muhammed H. Rahaman; Benjamin Noll; Sunita K. C. Basnet; Theodosia Teo; Hugo Albrecht; Robert Milne; Shudong Wang
Journal of Medicinal Chemistry, 2017
DOI: 10.1021/acs.jmedchem.6b01670
A Novel Series of N-(Pyridin-2-yl)-4-(Thiazol-5-yl)Pyrimidin-2-Amines as Highly Potent CDK4/6 inhibitors
Solomon Tadesse; Ge Zhu; Laychiluh B. Mekonnen; Jimma L. Lenjisa; Mingfeng Yu; Michael P. Brown; Shudong Wang
Future Medicinal Chemistry, 2017
DOI: 10.4155/fmc-2017-0076